Business
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025.
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025.","length":352,"tagName":"p"},{"type":"image","alt":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","displaySize":"","headline":null,"caption":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":185,"url":"https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vyx_W5YQZ5KQRkzzHXw_Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801","width":400,"height":185}},"href":"https://mma.prnewswire.com/media/2754298/CytoSorbents_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day.","length":154,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Details:Date: Thursday, November 13, 2025Time: 4:30 PM ETLive webcast lin...